Alcohol Biomarkers covers laboratory and digital measures that detect use patterns, quantify risk, and monitor treatment—PEth, EtG/EtS, CDT, GGT/AST/ALT, and emerging passive sensors. This page clarifies when to use each marker, how to interpret windows of detection, and how to combine tests with clinical context to avoid false reassurance or unwarranted sanctions. If you’re reviewing options for an alcohol biomarkers conference, you’ll find practical algorithms for baseline assessment, relapse monitoring, and documentation for workplaces, courts, and transplant evaluations. We explain trade-offs—sensitivity, specificity, cost, and logistics—and how social determinants (housing, transport, stigma) influence real-world feasibility and follow-up.

Clinical value depends on pairing biomarkers with patient-centred care. Link results to motivational conversations, contingency management, and adjustments in pharmacotherapy (acamprosate, naltrexone, disulfiram) or psychotherapy intensity. PEth supports medium-term monitoring; EtG/EtS detect recent use; CDT highlights sustained heavy drinking; LFT patterns add clinical context but are not specific. We discuss how to handle discordant results, set transparent thresholds, and communicate findings without shaming. For condition-level management, see Alcohol Use Disorder, which complements this page with diagnosis, medication selection, and relapse-prevention planning.